NCCN Announces Funding for a Prostate Cancer Research Project
NCCN Announces Funding for a Prostate Cancer Research Project
The National Comprehensive Cancer Network's Oncology Research Program's grant will advance scientific knowledge of hematologic toxicity of PARPi in the treatment of patients with prostate cancer.
国家综合癌症网络的肿瘤研究项目的资助将推进关于PARPi在前列腺癌患者治疗中血液毒性的科学知识。
PLYMOUTH MEETING, Pa., Dec. 11, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) today announced funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi). The award is supported by Pfizer Global Medical Grants and Partnerships.
宾夕法尼亚州普利茅斯会议,2024年12月11日 /PRNewswire/ -- 全国综合抗癌网络 (NCCN) 肿瘤研究计划 (ORP) 今天宣布了一项资助项目,该项目将支持对聚ADP核糖聚合酶抑制剂 (PARPi) 治疗所带来的副作用的最佳管理进行创新研究。该奖项由辉瑞全球医疗补助和合作伙伴关系支持。
PARPi treatment is associated with hematologic toxicity, often leading to dose modification, treatment interruption, discontinuation, or the need for enhanced supportive care interventions. Anemia is the most common side effect associated with PARPi in patients with metastatic castration-resistant prostate cancer (mCRPC), with about a quarter of patients reporting serious anemia shortly after PARPi initiation. The use of PARPi is expected to rise in the coming years, and their combination with other agents is already being examined in earlier disease settings.
PARPi治疗与血液毒性相关,通常导致剂量调整、治疗中断、停止治疗或需要加强压力位干预。贫血是与PARPi相关的最常见副作用,约四分之一的转移性去势抵抗性前列腺癌 (mCRPC) 患者在PARPi治疗刚开始后就报告有严重贫血。预计PARPi的使用将在未来几年上升,并且它们与其他药物的组合已经在早期疾病阶段进行研究。
"This work will enhance our understanding of how to better care for individuals with prostate cancer."
"这项工作将增强我们对如何更好照顾前列腺癌患者的理解。"
In the mCRPC population, there can be additional challenges due to advanced age, reduced bone strength, other co-existing medical conditions, as well as significant prior treatments that add to the risk of toxicities.
在mCRPC人群中,由于年龄较大、骨骼强度下降、其他共存疾病以及之前的重大治疗,这些因素可能增加毒性的风险,从而带来额外的挑战。
"The aim of this research is to advance our understanding and ability to reduce adverse effects from PARPi alone or in combination with other treatments for patients with prostate cancer," explained Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Congratulations to this remarkable investigator. This work will enhance our understanding of how to better care for individuals with prostate cancer."
"这项研究的目的是推进我们对如何单独或与其他治疗结合减少PARPi的副作用的理解和能力,并帮助前列腺癌患者," NCCN首席执行官Crystal S. Denlinger博士解释道。"祝贺这位杰出的研究者。这项工作将增强我们对如何更好照顾前列腺癌患者的理解。"
The selected project will be led by:
该项目将由以下人员领导:
-
David Link, MD, Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- Impact of Germline BRCA1/2 Mutations on PARPi-induced Anemia
- 大卫·林克,医学博士,巴恩斯-犹太医院西特曼抗癌中心和华盛顿大学医学院
- 生殖系BRCA1/2突变对PARPi引起的贫血的影响
"We are really pleased to support this important research and to collaborate with the National Comprehensive Cancer Network. Working with organizations like NCCN gives us the opportunity to accelerate and improve health outcomes for prostate cancer patients. We're working every day to reduce healthcare disparities by leading and contributing to a variety of initiatives, programs, partnerships, and investments including our support of this initiative," said Maureen Doyle-Scharff, PhD, FACEhp, Head of Global Medical Grants and Partnerships, Pfizer.
“我们非常高兴能够支持这项重要研究,并与国家综合抗癌网络合作。与NCCN等组织合作为我们提供了加速提高前列腺癌患者健康结果的机会。我们每天都在努力通过领导和参与多项倡议、项目、合作伙伴关系和投资,包括对该倡议的支持,来减少医疗差距,”辉瑞全球医疗资助与合作伙伴关系负责人毛琳·道尔-夏夫博士说。
Proposals were peer reviewed by a Scientific Review Committee, which consisted of leading expert oncologists from NCCN Member Institutions. The selected project is set to be completed within two years.
提案经过科学审查委员会的同行评审,该委员会由NCCN会员机构的顶尖肿瘤专家组成。选定的项目计划在两年内完成。
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of people with cancer and supports preclinical, translational, and clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website, an informed consent database, and points to consider on the best practices for biorepositories, registries, and databases. For more information, visit NCCN.org/orp.
NCCN ORP促进创新和知识发现,提高癌症患者的生活,并支持NCCN会员机构的临床前、转化和临床研究以及质量改进项目。为了改善癌症研究的合作,NCCN ORP还维护共享资源网站、知情同意数据库,以及有关生物样本库、注册和数据库最佳实践的考虑要点。有关更多信息,请访问NCCN.org/orp。
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
关于国家综合抗癌网络
国家综合抗癌网络(NCCN)是一个非营利性的领先癌症中心联盟,致力于患者护理、研究和教育。NCCN致力于定义和推动优质、有效、公平和可及的癌症护理,以便所有人都能过上更好的生活。NCCN肿瘤学临床实践指南(NCCN Guidelines)提供透明的、基于证据的、专家共识驱动的癌症治疗、预防和支持服务的建议;它们被公认为癌症管理和政策的临床方向和标准,并且是医学领域中更新最彻底和频繁的临床实践指南。NCCN患者指南提供专家的癌症治疗信息,以告知和赋能患者及照顾者,得益于NCCN基金会的支持。NCCN还推动继续教育、全球倡议、政策、研究合作和肿瘤学出版。有关更多信息,请访问NCCN.org。
Media Contact:
Rachel Darwin
267-622-6624
[email protected]
媒体联系人:
瑞秋·达尔文
267-622-6624
[email protected]
SOURCE National Comprehensive Cancer Network
来源:全国综合抗癌网络